Author

Lyh Ping Lam

Observed names: L.P. Lam, Lyh-Ping Lam

Institutions: Beth Israel Deaconess Medical Center, Hackensack University Medical Center, Mayo Clinic, VA Boston Healthcare System, Massachusetts General Hospital, Dana-Farber Cancer Institute, Tennessee Oncology, Bluebird Bio (United States)

Observed institutions: Beth Israel Deaconess Medical Center, Hackensack University Medical Center, Mayo Clinic, VA Boston Healthcare System, Massachusetts General Hospital, Dana-Farber Cancer Institute, Tennessee Oncology, Bluebird Bio (United States)

OpenAlex ID: A5113849996

Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma

2019 · Noopur Raje, Jesus Berdeja, et al. · New England Journal of Medicine · 1,728

Initial Results from a Phase 1 Clinical Study of bb21217, a Next-Generation Anti Bcma CAR T Therapy

2018 · Nina Shah, Melissa Alsina, et al. · Blood · 85

Durable Clinical Responses in Heavily Pretreated Patients with Relapsed/Refractory Multiple Myeloma: Updated Results from a Multicenter Study of bb2121 Anti-Bcma CAR T Cell Therapy

2017 · Jesus G. Berdeja, Yi Lin, et al. · Blood · 85

Updated Results from an Ongoing Phase 1 Clinical Study of bb21217 Anti-Bcma CAR T Cell Therapy

2019 · Jesus G. Berdeja, Melissa Alsina, et al. · Blood · 63

bb2121 anti-BCMA CAR T-cell therapy in patients with relapsed/refractory multiple myeloma: Updated results from a multicenter phase I study.

2018 · Noopur S. Raje, Jesus G. Berdeja, et al. · Journal of Clinical Oncology · 59

First-in-human multicenter study of bb2121 anti-BCMA CAR T-cell therapy for relapsed/refractory multiple myeloma: Updated results.

2017 · Jesus G. Berdeja, Yi Lin, et al. · Journal of Clinical Oncology · 57

Clinical remissions and limited toxicity in a first-in-human multicenter study of bb2121, a novel anti-BCMA CAR T cell therapy for relapsed/refractory multiple myeloma

2016 · J.G. Berdeja, Y. Lin, et al. · European Journal of Cancer · 13

Early MRD negativity to predict deepening myeloma response in relapsed/refractory multiple myeloma (RRMM) patients treated with bb2121 anti-BCMA CAR T cells.

2018 · Nikhil C. Munshi, Jesus G. Berdeja, et al. · Journal of Clinical Oncology · 10

Association of high baseline ferritin with tocilizumab administration for CRS in relapsed/refractory multiple myeloma patients treated with bb2121 anti-BCMA CAR T cells.

2018 · Jesus G. Berdeja, Yi Lin, et al. · Journal of Clinical Oncology

Works count: 9

Citation count: 2,100

H-index: 8

I10-index: 8